<DOC>
	<DOCNO>NCT02226003</DOCNO>
	<brief_summary>This study evaluate efficacy safety ertugliflozin ( MK-8835/PF-04971729 ) combination sitagliptin treatment participant Type 2 diabetes mellitus ( T2DM ) inadequate glycemic control diet exercise . The primary hypothesis study ertugliflozin plus sitagliptin effective lower hemoglobin A1C ( HbA1C ) placebo .</brief_summary>
	<brief_title>Efficacy Safety Ertugliflozin ( MK-8835/PF-04971729 ) With Sitagliptin Treatment Participants With Type 2 Diabetes Mellitus ( T2DM ) With Inadequate Glycemic Control Diet Exercise ( MK-8835-017 )</brief_title>
	<detailed_description>Each participant study approximately 39 week include : 1-week screening period , 8-week ( great ) antihyperglycemic agent ( AHA ) wash-off period , 2-week single-blind placebo run-in period , 26-week double-blind treatment period , post-treatment telephone contact 14 day last dose study drug .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes mellitus per American Diabetes Association guideline Not antihyperglycemic agent ( AHA ) &gt; =8 week Visit 1/Screening HbA1C &gt; =8.0 % &lt; =10.5 % ( &gt; =64 mmol/mol &lt; =91 mmol/mol ) OR single allowable AHA ( allowable AHAs prior screening : metformin , αglucosidase inhibitor , sulfonylurea glinides ) Visit 1/Screening HbA1C &gt; =7.5 % &lt; =10.0 % ( &gt; =58 mmol/mol &lt; =86 mmol/mol ) OR lowdose dual combination therapy ( ≤50 % maximum label dose AHA ) allowable AHAs Visit 1/Screening HbA1C &gt; =7.5 % &lt; =10.0 % ( &gt; =58 mmol/mol &lt; =86 mmol/mol ) Body mass index ( BMI ) &gt; =18.0 kg/m^2 Male female reproductive potential Female reproductive potential agrees ( partner agree ) remain abstinent heterosexual activity use 2 acceptable combination contraception . History type 1 diabetes mellitus diabetic ketoacidosis History specific type diabetes ( e.g. , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrinopathies , drug chemicalinduced , postorgan transplant A know hypersensitivity intolerance sodium glucose cotransporter ( SGLT2 ) inhibitor sitagliptin Has treat follow agent within 12 week study start prerandomization period : insulin type ( except shortterm use [ i.e. , &lt; =7 day ] concomitant illness stress ) , injectable antihyperglycemic agent ( e.g. , pramlintide , exenatide , liraglutide ) , pioglitazone rosiglitazone , sodium glucose cotransporter 2 ( SGLT2 ) inhibitor , dipeptidylpeptidase 4 inhibitor ( DPP4 inhibitor ) , bromocriptine ( Cycloset™ ) , colesevelam ( Welchol™ ) , AHA exception protocolapproved agent Is weightloss program weightloss medication medication associate weight change weight stable prior study start Has undergone bariatric surgery within past 12 month &gt; 12 month weight stable prior study start A history myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional Class IIIIV heart failure within 3 month study start Active , obstructive uropathy indwell urinary catheter History malignancy &lt; =5 year prior study start , except adequately treat basal cell squamous cell skin cancer situ cervical cancer A know history human immunodeficiency virus ( HIV ) A blood dyscrasia disorder cause hemolysis unstable red blood cell , clinically important hematological disorder ( e.g . aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) A medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Any clinically significant malabsorption condition Current treatment hyperthyroidism On thyroid replacement therapy stable dose least 6 week prior study start On previous clinical study ertugliflozin Participated study involve investigational drug ( ) 30 day prior study start Surgical procedure within 6 week prior study start major surgery plan trial Positive urine pregnancy test Pregnant breastfeeding , plan conceive trial , include 14 day follow last dose study medication Planning undergo hormonal therapy preparation egg donation trial , include 14 day follow last dose study medication Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week engages binge drink Donated blood blood product within 6 week study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>